| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Department of Retroviral Regulation, Medical Research Division, Tokyo Medical and Dental University, Tokyo 113-8519 [H. S., Y. I., N. O.], and Department of Immunology, Juntendo University School of Medicine, Tokyo 113-8421 [H. Y.], Japan
Recent studies have revealed that a variety of malignant tumors express Fas and/or its ligand FasL. However, tumor cells expressing Fas are not always susceptible to Fas-mediated cell death, and the biological significance of simultaneous expression of Fas and FasL in the same tumor is not known. In the present study, we addressed this question in three glioma cells lines, A-172, T98G, and YKG-1, which express both Fas and FasL endogenously and their Fas transfectants. We report here that: (a) in gliomas, [3H]TdR incorporation was enhanced by anti-Fas IgM monoclonal antibody CH-11 and conversely inhibited by anti-FasL monoclonal antibody NOK-2; (b) cross-linking of Fas with CH-11 drove both cell cycle progression and apoptosis as demonstrated by the induction of the S-G2 phase of DNA and RNA and fragmented nuclei; (c) phosphorylation of extracellular signal-regulated kinase (ERK), but not of c-Jun NH2-terminal kinase or p38, was induced by cross-linking of Fas; (d) a mitogen-activated protein kinase/ERK kinase 1 (MEK1) inhibitor PD98059 completely blocked CH-11-induced ERK phosphorylation as well as cell cycle progression without affecting induction of apoptosis; and (e) a broad-spectrum caspase inhibitor Z-Asp-CH2-DCB inhibited CH-11-induced ERK phosphorylation, cell cycle progression, and apoptosis. These results indicate that Fas-mediated caspase activation elicits two independent cellular responses; one is to induce apoptosis and another is to promote cell cycle progression; the latter is closely linked to the MEK-ERK pathway. Together, our data strongly suggest that FasL may play a role as an autocrine growth factor in gliomas.
This article has been cited by other articles:
![]() |
Y. Zhang, Q. Liu, M. Zhang, Y. Yu, X. Liu, and X. Cao Fas Signal Promotes Lung Cancer Growth by Recruiting Myeloid-Derived Suppressor Cells via Cancer Cell-Derived PGE2 J. Immunol., March 15, 2009; 182(6): 3801 - 3808. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Matsubara, M. Watanabe, T. Imai, Y. Yui, Y. Mizushima, Y. Hiraumi, Y. Kamitsuji, K.-i. Watanabe, K. Nishijo, J. Toguchida, et al. Involvement of Extracellular Signal-Regulated Kinase Activation in Human Osteosarcoma Cell Resistance to the Histone Deacetylase Inhibitor FK228 [(1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone] J. Pharmacol. Exp. Ther., March 1, 2009; 328(3): 839 - 848. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Mao, S. Gundavarapu, C. Patel, A. Tsai, F. I. Luks, and M. E. De Paepe The Fas System Confers Protection against Alveolar Disruption in Hyperoxia-Exposed Newborn Mice Am. J. Respir. Cell Mol. Biol., December 1, 2008; 39(6): 717 - 729. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Ruan, C. T. Lee, and J. Desbarats A Novel Juxtamembrane Domain in Tumor Necrosis Factor Receptor Superfamily Molecules Activates Rac1 and Controls Neurite Growth Mol. Biol. Cell, August 1, 2008; 19(8): 3192 - 3202. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Li, X. Cai, X. Fan, B. Moquin, C. Stoicov, and J. Houghton Fas Ag-FasL coupling leads to ERK1/2-mediated proliferation of gastric mucosal cells Am J Physiol Gastrointest Liver Physiol, January 1, 2008; 294(1): G263 - G275. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zhang, S. Shimizu, K. Sakamaki, S. Yonehara, and Y. Tsujimoto A Caspase-8-independent Signaling Pathway Activated by Fas Ligation Leads to Exposure of the Bak N Terminus J. Biol. Chem., August 6, 2004; 279(32): 33865 - 33874. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wu, M. A. McKenna, X. Feng, T. R. Nagy, and J. M. McDonald Osteoclast Apoptosis: The Role of Fas in Vivo and in Vitro Endocrinology, December 1, 2003; 144(12): 5545 - 5555. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Rajesh, R. A. Stenzel, and S. P. Howard Perillyl Alcohol as a Radio-/Chemosensitizer in Malignant Glioma J. Biol. Chem., September 19, 2003; 278(38): 35968 - 35978. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. J. Spierings, E. G. E. de Vries, W. Timens, H. J. M. Groen, H. M. Boezen, and S. de Jong Expression of TRAIL and TRAIL Death Receptors in Stage III Non-Small Cell Lung Cancer Tumors Clin. Cancer Res., August 1, 2003; 9(9): 3397 - 3405. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. F. Yang, C. Xiao, W. H. Roa, P. H. Krammer, and C. Hao Calcium/Calmodulin-dependent Protein Kinase II Regulation of c-FLIP Expression and Phosphorylation in Modulation of Fas-mediated Signaling in Malignant Glioma Cells J. Biol. Chem., February 21, 2003; 278(9): 7043 - 7050. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Li and J. R. Bertino Fas-mediated Signaling Enhances Sensitivity of Human Soft Tissue Sarcoma Cells to Anticancer Drugs by Activation of p38 Kinase Mol. Cancer Ther., December 1, 2002; 1(14): 1343 - 1348. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-C. Huang, M.-J. Tang, K.-F. Hsu, Y.-M. Cheng, and C.-Y. Chou Fas and Its Ligand, Caspases, and Bcl-2 Expression in Gonadotropin-Releasing Hormone Agonist-Treated Uterine Leiomyoma J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4580 - 4586. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-H. Ahn, S.-M. Park, H.-S. Cho, M.-S. Lee, J.-B. Yoon, J. Vilcek, and T. H. Lee Non-apoptotic Signaling Pathways Activated by Soluble Fas Ligand in Serum-starved Human Fibroblasts. MITOGEN-ACTIVATED PROTEIN KINASES AND NF-kappa B-DEPENDENT GENE EXPRESSION J. Biol. Chem., December 7, 2001; 276(50): 47100 - 47106. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Choi, X. Xu, J.-W. Oh, S. J. Lee, G. Y. Gillespie, H. Park, H. Jo, and E. N. Benveniste Fas-induced Expression of Chemokines in Human Glioma Cells: Involvement of Extracellular Signal-regulated Kinase 1/2 and p38 Mitogen-activated Protein Kinase Cancer Res., April 1, 2001; 61(7): 3084 - 3091. [Abstract] [Full Text] |
||||
![]() |
G. H. Gibbons and M. J. Pollman Death Receptors, Intimal Disease, and Gene Therapy : Are Therapies That Modify Cell Fate Moving too Fas? Circ. Res., May 26, 2000; 86(10): 1009 - 1012. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |